GSK Nov 2024 36.000 call
| Previous close | 8.20 |
| Open | 8.20 |
| Bid | 8.10 |
| Ask | 10.70 |
| Strike | 36.00 |
| Expiry date | 2024-11-15 |
| Day's range | 8.20 - 8.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 29 |
BloombergGSK Plunges as Drugmaker Must Face Zantac Cases in Delaware
(Bloomberg) -- GSK Plc shares plunged in the wake of a court ruling that the UK drugmaker, alongside others including Sanofi, must face trials over whether the former heartburn treatment Zantac causes cancer. Most Read from BloombergKey Engines of US Consumer Spending Are Losing Steam All at OnceGameStop Shares Double as Gill Post Shows $116 Million BetHomebuyers Are Starting to Revolt Over Steep Prices Across USMnuchin Chases Wall Street Glory With His War Chest of Foreign MoneyNvidia Unveils N
Evening StandardFTSE 100 Live 3 June: GSK shares tumble, Monzo turns first profit
GSK shares are today’s major focus after the drugs giant’s defence against Zantac claims suffered a setback in a Delaware court. The FTSE 100 index is trading higher after Friday’s late rally by Wall Street markets was further boosted by this week’s prospect of an ECB interest rate cut. Other companies in the spotlight today include FTSE 250-listed Hollywood Bowl, having posted an 11% rise in half-year profits.
Business WireBelantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
PHILADELPHIA, June 02, 2024--Belantamab Mafodotin combo reduced the risk of disease progression or death by nearly 50% versus SOC combo in relapsed/refractory multiple myeloma
